There is a particular kind of patient who will walk into a memory clinic over the next few years feeling entirely well. No forgotten appointments, no wandering thoughts mid-sentence, no family member quietly worried at the dinner table. They will be there because a blood test told them something their brain has not yet told them itself: that the biological process behind Alzheimer's disease may already be under way. This is the premise of the Phase III trial now recruiting roughly 1,600 adults aged 55 to 80 across international sites, including the UK, and it marks a genuine break from how dementia has been treated for the past two decades. The ambition is not to slow decline once it has begun. It is to intervene before a patient or their family notices anything wrong at all.

The mechanics are, on their own terms, elegant. A blood biomarker identifies early protein changes in the brain long before symptoms surface. An experimental drug, already shown to clear these deposits in patients with early-stage disease, is then tested on people who are asymptomatic, in the hope that removal before onset prevents the clinical disease from ever arriving. Over four to six years, researchers will find out whether prevention is possible in a way that treatment, so far, has not managed.

The scientific case is credible enough to take seriously. The NHS case is more complicated, and that is where the story becomes less about laboratory promise and more about institutional readiness.

Preventative dementia care of this kind requires a diagnostic infrastructure that does not yet exist at scale in Britain. Memory services are already stretched by referral backlogs and inconsistent access across integrated care boards, built around confirming a diagnosis in people who present with symptoms, not screening healthy adults for a biomarker they did not know to ask about. Blood-based testing for amyloid and tau markers is still working its way through validation and commissioning discussions, and turning a research-grade assay into something GPs can order routinely, at a cost and volume the NHS can absorb, is a slower and less glamorous task than the trial itself.

Then there is the question of what happens if the drug works. Anti-amyloid therapies that have already reached appraisal in the UK, treating symptomatic patients rather than preventing disease, have run into NICE's cost-effectiveness thresholds despite regulatory approval elsewhere. A prevention drug administered to large numbers of healthy people, requiring infusion capacity, monitoring for side effects such as brain swelling, and years of follow-up before any benefit is provable, presents a health economics problem considerably harder than the one NICE has already found difficult. Approval without a workable funding and delivery pathway would leave patients identified as at risk with nowhere to go, which is arguably worse than not testing them in the first place.

There is also a workforce dimension that tends to be left out of the science coverage. Neurologists, memory nurses and radiologists are already in short supply relative to demand, and a preventative model multiplies the population that needs specialist attention rather than concentrating it on those already unwell. Somebody has to read the scans, deliver the infusions and manage the anxiety of patients told they carry risk for a disease that may never manifest.

None of this diminishes the trial's significance. Hosting it signals that Britain remains a credible site for late-stage neuroscience research, which matters to a life sciences sector the government has repeatedly said it wants to grow. But there is a meaningful difference between hosting a breakthrough and being able to deliver one. If this drug succeeds, the harder work will not be proving it clears protein from the brain. It will be building, from a standing start, the diagnostic and workforce capacity to act on what it finds. That work has not begun, and four to six years is not a long time to start it.

‍